Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification

Why this matters for patients and doctors

Many older adults are told they have a "precancerous" blood condition called MGUS, which can be frightening even though most never develop cancer. This study looks at a specific form, light chain MGUS (LC‑MGUS), and tests new diagnostic rules that aim to distinguish people who truly need long‑term follow‑up from those who can safely be told that their blood tests are essentially normal. The findings suggest that better cutoffs for a key lab test can spare many people an alarming label, while focusing attention on the smaller group that really is at higher risk.

Understanding a quiet precursor to blood cancer

MGUS is a common, symptom‑free condition in which a small clone of plasma cells in the bone marrow produces an abnormal protein. In LC‑MGUS, this protein consists only of "light chains," fragments of antibodies that can be measured in the blood as free light chains (FLCs). Most people with LC‑MGUS never develop multiple myeloma, amyloidosis, or related blood cancers, but a minority do, making accurate diagnosis and risk assessment crucial. Until recently, doctors have relied on FLC reference ranges derived from a small, older study, even though later work suggested these ranges may misclassify many healthy people as abnormal—especially those with mild kidney problems or age‑related changes.

New cutoffs from a massive screening project

The iStopMM study in Iceland screened more than 75,000 individuals and proposed updated reference intervals for the FLC test that adjust for age and kidney function. Using these new ranges, the definition of LC‑MGUS was tightened: a person must still have an abnormal FLC ratio and a raised “involved” light chain, but the thresholds are recalibrated to better reflect what is truly abnormal in the general population. Earlier analyses in screened groups suggested that the new criteria sharply reduce how often LC‑MGUS is diagnosed, without missing people who go on to serious disease. The current paper asks whether these benefits also hold in real‑world clinic patients, where blood tests are ordered because of symptoms or other medical concerns, not population screening.

What the Danish cohort revealed

The researchers used a nationwide Danish data resource that links cancer diagnoses, laboratory results, and hospital records for adults evaluated between 2007 and 2024. They identified people coded as having MGUS who had the relevant FLC tests, and then re‑classified them according to both the original and revised LC‑MGUS criteria. Out of 360 people who met the old definition, only 215 met the revised definition; 150 (about 40%) were reclassified as having normal FLC values under the new rules. These reclassified individuals were overwhelmingly of the kappa light‑chain type, reflecting a known tendency of the older cutoffs and the commonly used assay to over‑call mild kappa elevations. In contrast, the revised criteria picked up a handful of lambda‑type cases that the old rules had missed, and two of these later developed multiple myeloma, supporting the idea that the new definition improves detection of truly important disease.

Who actually progressed to serious disease

Participants were followed for a median of almost four years to see who progressed to multiple myeloma, amyloidosis, or other lymphoid cancers. Among those who met the revised LC‑MGUS definition, 21 people (about 10%) progressed, including 11 to multiple myeloma and seven to amyloidosis, corresponding to an annual progression risk of roughly 3%. By contrast, in the reclassified group—those who no longer met the LC‑MGUS criteria—only two people progressed, both to types of lymphoma rather than myeloma or amyloidosis. No one in this group developed the plasma‑cell cancers that LC‑MGUS is meant to predict. Overall, people reclassified as normal had a progression rate about ten times lower than those who still met the revised LC‑MGUS definition.

Refining who is at highest risk

The authors also explored which features among those with revised LC‑MGUS signaled higher danger. Surprisingly, very high FLC ratios—above commonly used cutoffs such as 8 or 10—did not clearly separate those who progressed from those who did not, especially for amyloidosis. However, having the lambda light‑chain type was linked to a higher overall risk of progression than the kappa type. A reduction in normal antibody levels (immunoparesis), previously suggested as a risk factor, did not show a strong effect here, although the study size may limit firm conclusions. These findings point to the need for more nuanced risk models that go beyond a single lab threshold and combine several pieces of information.

What this means for patients and care systems

For patients, the key message is reassuring: using the revised FLC reference ranges safely removes LC‑MGUS labels from many people who are very unlikely to develop myeloma or amyloidosis. For doctors and health systems, the study shows that adopting the new criteria can cut LC‑MGUS diagnoses by about 40%, reducing unnecessary scans, bone‑marrow biopsies, clinic visits, and the anxiety that comes with being told one has a premalignant condition. At the same time, those who still meet the stricter definition appear to have a higher true risk of progression than earlier estimates suggested, making it more worthwhile to monitor them carefully. In short, better calibrated test cutoffs help ensure that follow‑up and concern are focused on the people who genuinely need them, while many others can be spared a worrying diagnosis.

Citation: Andersen, L.S., Mæng, C.V., Rögnvaldsson, S. et al. Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification. Blood Cancer J. 16, 50 (2026). https://doi.org/10.1038/s41408-026-01478-y

Keywords: light chain MGUS, free light chain testing, multiple myeloma risk, diagnostic criteria, monoclonal gammopathy